DRUG INTERVENTION RESPONSE PREDICTIONS WITH PARADIGM (DIRPP) IDENTIFIES DRUG RESISTANT CANCER CELL LINES AND PATHWAY MECHANISMS OF RESISTANCE

被引:0
作者
Brubaker, Douglas [1 ,2 ]
Difeo, Analisa [2 ]
Chen, Yanwen [2 ]
Pearl, Taylor [4 ]
Zhai, Kaide [2 ]
Bebek, Gurkan [1 ,2 ,3 ]
Chance, Mark [1 ,2 ]
Barnholtz-Sloan, Jill [1 ,2 ]
机构
[1] Case Western Reserve Univ, Sch Med, Case Ctr Prote & Bioinformat, BRB 932,10900 Euclid Ave, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
[3] Cleveland Clin, Lerner Res Inst, Genom Med Inst, Cleveland, OH 44195 USA
[4] MIT, Cambridge, MA 02139 USA
来源
PACIFIC SYMPOSIUM ON BIOCOMPUTING 2014 | 2014年
关键词
EXPRESSION;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The revolution in sequencing techniques in the past decade has provided an extensive picture of the molecular mechanisms behind complex diseases such as cancer. The Cancer Cell Line Encyclopedia (CCLE) and The Cancer Genome Project (CGP) have provided an unprecedented opportunity to examine copy number, gene expression, and mutational information for over 1000 cell lines of multiple tumor types alongside IC50 values for over 150 different drugs and drug related compounds. We present a novel pipeline called DIRPP, Drug Intervention Response Predictions with PARADIGM7, which predicts a cell line's response to a drug intervention from molecular data. PARADIGM (Pathway Recognition Algorithm using Data Integration on Genomic Models) is a probabilistic graphical model used to infer patient specific genetic activity by integrating copy number and gene expression data into a factor graph model of a cellular network. We evaluated the performance of DIRPP on endometrial, ovarian, and breast cancer related cell lines from the CCLE and CGP for nine drugs. The pipeline is sensitive enough to predict the response of a cell line with accuracy and precision across datasets as high as 80 and 88% respectively. We then classify drugs by the specific pathway mechanisms governing drug response. This classification allows us to compare drugs by cellular response mechanisms rather than simply by their specific gene targets. This pipeline represents a novel approach for predicting clinical drug response and generating novel candidates for drug repurposing and repositioning.
引用
收藏
页码:125 / 135
页数:11
相关论文
共 48 条
  • [31] Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway
    Ahn, Hee-Jin
    Kim, Gwangil
    Park, Kyung-Soon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 437 (04) : 557 - 564
  • [32] Association of transcriptional levels of folate-mediated one-carbon metabolism-related genes in cancer cell lines with drug treatment response
    Min, Dong-Joon
    Vural, Suleyman
    Krushkal, Julia
    CANCER GENETICS, 2019, 237 : 19 - 38
  • [33] Dark Sweet Cherry (Prunus avium L.) Juice Phenolics Rich in Anthocyanins Exhibit Potential to Inhibit Drug Resistance Mechanisms in 4T1 Breast Cancer Cells via the Drug Metabolism Pathway
    Nava-Ochoa, Ana
    Mertens-Talcott, Susanne U.
    Talcott, Stephen T.
    Noratto, Giuliana D.
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (03)
  • [34] Met Signaling Cascade Is Amplified by the Recruitment of Phosphorylated Met to Lipid Rafts via CD24 and Leads to Drug Resistance in Endometrial Cancer Cell Lines
    Ono, Yoshihiro Joshua
    Tanabe, Akiko
    Tanaka, Tomohito
    Tanaka, Yoshimichi
    Hayashi, Masami
    Terai, Yoshito
    Ohmichi, Masahide
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2353 - 2363
  • [35] Cytotoxicity of four Aframomum species (A. arundinaceum, A. alboviolaceum, A. kayserianum and A. polyanthum) towards multi-factorial drug resistant cancer cell lines
    Kuete, Victor
    Ango, Patrick Y.
    Yeboah, Samuel O.
    Mbaveng, Armelle T.
    Mapitse, Renameditswe
    Kapche, Gilbert D. W. F.
    Ngadjui, Bonaventure T.
    Efferth, Thomas
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14
  • [36] Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene
    Yahya, Shaymaa M. M.
    Nabih, Heba K.
    Elsayed, Ghada H.
    Mohamed, Shimaa Ibrahim Abdelmenym
    Elfiky, Asmaa M.
    Salem, Sohair M.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 133 - 149
  • [37] Letter to editor regarding "GLI1 overexpression promotes gastric cancer cell proliferation and migration and induces drug resistance by combining with the AKT-mTOR pathway"
    Tang, Chao-Tao
    Zeng, Chun-Yan
    Chen, You-Xiang
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 122
  • [38] CPNE1 Enhances Colorectal Cancer Cell Growth, Glycolysis, and Drug Resistance Through Regulating the AKT-GLUT1/HK2 Pathway
    Wang, Yuexia
    Pan, Shengli
    He, Xinhong
    Wang, Ying
    Huang, Haozhe
    Chen, Junxiang
    Zhang, Yuhao
    Zhang, Zhijin
    Qin, Xianju
    ONCOTARGETS AND THERAPY, 2021, 14 : 699 - 710
  • [39] Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line
    Zhang, Ke
    Wang, Xian
    Wang, Hongyan
    MOLECULAR MEDICINE REPORTS, 2014, 10 (04) : 2065 - 2072
  • [40] A novel inhibitor of fatty acid synthase shows activity against HER2+breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
    Puig, Teresa
    Aguilar, Helena
    Cufi, Silvia
    Oliveras, Gloria
    Turrado, Carlos
    Ortega-Gutierrez, Silvia
    Benhamu, Bellinda
    Luz Lopez-Rodriguez, Maria
    Urruticoechea, Ander
    Colomer, Ramon
    BREAST CANCER RESEARCH, 2011, 13 (06)